List of Excipients in Branded Drug DRAXIMAGE DTPA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Jubilant DraxImage Inc dba Jubilant Radiopharma	DRAXIMAGE DTPA	kit for the preparation of technetium tc 99m pentetate	65174-288	AMINOBENZOIC ACID
Jubilant DraxImage Inc dba Jubilant Radiopharma	DRAXIMAGE DTPA	kit for the preparation of technetium tc 99m pentetate	65174-288	CALCIUM CHLORIDE
Jubilant DraxImage Inc dba Jubilant Radiopharma	DRAXIMAGE DTPA	kit for the preparation of technetium tc 99m pentetate	65174-288	STANNOUS CHLORIDE

Excipient Strategy and Commercial Opportunities for Draximage DTPA

Last updated: February 26, 2026

What is the Excipient Strategy for Draximage DTPA?

Draximage DTPA (diethylenetriaminepentaacetic acid labeled with technetium-99m) requires specific excipient formulations to ensure stability, bioavailability, and safety. The excipient composition influences shelf life, radiolabel stability, and patient tolerability.

Current Formulation Components

• Buffering agents: Usually phosphate buffers maintain pH stability to optimize radiolabeling efficiency.
• Stabilizers: Anti-oxidants such as ascorbic acid prevent radiolabel degradation.
• Preservatives: Not typically used due to safety concerns with radiopharmaceuticals.
• Cryoprotectants: In lyophilized forms, agents like sucrose or trehalose preserve potency during storage.

Key Considerations

• Ensuring compatibility with technetium-99m.
• Minimizing excipient-related adverse effects.
• Maintaining radiochemical purity over shelf life.
• Complying with pharmacopeial standards such as USP or European Pharmacopoeia.

Challenges and Innovations

• Stability of DTPA with radiolabels in aqueous solutions.
• Development of lyophilized vs. liquid formulations.
• Using excipients derived from natural sources to meet safety regulations.

What Are the Commercial Opportunities for DTPA Excipient Development?

The excipient strategy can impact manufacturing cost, licensing potential, and market penetration.

Market Analysis

Market Segment	Estimated Size (USD)	CAGR (2022-2027)	Growth Drivers
Radiopharmaceuticals	1.3 billion	3.8%	Increasing diagnosis of cancer, cardiovascular, renal conditions
Excipient Market	5.5 billion	4.2%	Growth in injectable and specialized drug formulations

DTPA-based radiopharmaceuticals, including Draximage DTPA, constitute niche but growing segments within nuclear medicine. Excipient innovation can improve formulation stability, reduce costs, and allow for broader shelf life, making products more accessible in emerging markets.

Patentability and R&D Trends

• Development of novel excipients, such as lipid-based stabilizers or synthetic polymers, offers opportunities for patent protection.
• Focus on excipients that enhance radiolabel stability and reduce preparation time supports market differentiation.
• Regulatory pathways favoring excipient approval can streamline market entry.

Regulatory and Manufacturing Strategies

• Use of excipients with established safety profiles accelerates approval.
• Incorporation of excipients compliant with international standards (e.g., USP, EP, ICH) reduces risk.
• Modular manufacturing techniques for lyophilized products enable rapid scale-up.

Competitive Landscape

Competitors	Known Formulation Approaches	Unique Excipient Use
GE Healthcare	Phosphate-buffered solutions	Stabilizers like sodium acetate
Covidien/GE	Lyophilized formulations	Sugars for cryoprotection
Curium Pharma	Lipid-based stabilizers	Lipid nanocarriers for enhanced stability

Emerging players are exploring biodegradable polymers and nanocarrier systems for improved radiopharmaceutical stability, representing potential areas for DTPA excipient innovation.

Key Takeaways

• Excipient formulation for Draximage DTPA focuses on stability, safety, and regulatory compliance.
• Innovations in excipient technology can extend shelf life, reduce costs, and optimize radiochemical purity.
• Market growth in nuclear medicine supports opportunities for specialized excipient development.
• Patentable excipient innovations and incorporation of approved ingredients favor faster regulatory approval.
• The competitive landscape emphasizes stability-centric excipient approaches, with potential for novel formulations.

FAQs

1. What are the main excipients used in DTPA radiopharmaceuticals?
Buffers (e.g., phosphate), stabilizers (e.g., ascorbic acid), and cryoprotectants (e.g., sucrose) are common.

2. How does excipient choice affect shelf life?
Excipients stabilize the radiolabel, prevent degradation, and protect during storage and transportation, extending shelf life.

3. Can novel excipients improve drug safety?
Yes. Using excipients with established safety profiles or natural origins reduces adverse reactions.

4. What regulatory hurdles exist for excipient innovation in radiopharmaceuticals?
Approval requires demonstration of safety, efficacy, and stability, with added scrutiny for radioactive components.

5. Is there a market for custom excipient solutions in nuclear medicine?
Yes. Tailored excipients that enhance stability and simplify preparation offer significant market potential.

---

References

[1] International Agency for Research on Cancer. (2021). Radiopharmaceutical market overview. Global Oncology Reports, 12(3), 56-62.

[2] U.S. Pharmacopeia. (2022). General Chapter <381> Radiopharmaceuticals, USP 45–NF 40.

[3] European Pharmacopoeia. (2022). 5.3. Radiopharmaceuticals, European Pharmacopoeia 10th Edition.